IVIM Health vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, IVIM Health↗ is cheaper: $278 versus $399 a month all-in — a $121 monthly gap, $1,452 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, IVIM Health is cheaper: $149 versus $299 a month all-in — a $150 monthly gap, $1,800 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

IVIM Health: the record, condensed

On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Pricing steps with the dose here: from $208 at entry to $278 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $840 a year, which is why every ranking on this site uses the larger number.

Inside that $278 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $203, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Remedy Meds: the record, condensed

On tirzepatide, the number that matters at Remedy Meds is $399 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $399 is the whole subscription, which makes Remedy Meds unusually easy to compare and unusually easy to leave.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

Start with the load-bearing figure: $299 a month, all-in, is what Remedy Meds charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes Remedy Meds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: IVIM Health at $278, Remedy Meds at $399 — a $121 monthly spread that compounds to $1,452 over a maintenance year and $2,904 over two.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while IVIM Health’s is not — so Remedy Meds’s number is a ceiling and IVIM Health’s advertised entry ($208) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

IVIM Health’s total includes a mandatory $75/month membership; Remedy Meds has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $149 (IVIM Health) against $299 (Remedy Meds). $150 a month sounds survivable; $1,800 a year is a decision.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while IVIM Health’s is not — so Remedy Meds’s number is a ceiling and IVIM Health’s advertised entry ($149) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

IVIM Health’s total includes a mandatory $75/month membership; Remedy Meds has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

A way to feel the $121 monthly gap: over a year it funds 5.2 extra months at IVIM Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $2,904, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: IVIM Health $278/mo month-to-month against Remedy Meds $399/mo month-to-month. The order holds: IVIM Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: IVIM Health $834 monthly; Remedy Meds $1,197 monthly — best path favors IVIM Health by $363. 6 months: IVIM Health $1,668 monthly; Remedy Meds $2,394 monthly — best path favors IVIM Health by $726. 12 months: IVIM Health $3,336 monthly; Remedy Meds $4,788 monthly — best path favors IVIM Health by $1,452. 24 months: IVIM Health $6,672 monthly; Remedy Meds $9,576 monthly — best path favors IVIM Health by $2,904.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: IVIM Health $447 vs Remedy Meds $897 — $450 to IVIM Health. 6 mo: IVIM Health $894 vs Remedy Meds $1,794 — $900 to IVIM Health. 12 mo: IVIM Health $1,788 vs Remedy Meds $3,588 — $1,800 to IVIM Health. 24 mo: IVIM Health $3,576 vs Remedy Meds $7,176 — $3,600 to IVIM Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: IVIM Health publishes “not published”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: IVIM Health — membership mandatory for duration; membership mandatory. Remedy Meds — unknown; not published.

Evidence: IVIM Health source-verified (captured 2026-08-05); Remedy Meds third-party reported (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #3 and #15 of 17: between them lie 11 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #3 and #19 of 20: between them lie 15 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between IVIM Health and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (IVIM Health: membership mandatory; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings